Literature DB >> 26536111

Brain tumour cells interconnect to a functional and resistant network.

Matthias Osswald1,2, Erik Jung1,2, Felix Sahm3,4, Gergely Solecki1,2, Varun Venkataramani5, Jonas Blaes1,2, Sophie Weil1,2, Heinz Horstmann5, Benedikt Wiestler1,2,6, Mustafa Syed1,2, Lulu Huang1,2, Miriam Ratliff2,7, Kianush Karimian Jazi1,2, Felix T Kurz8, Torsten Schmenger1,2, Dieter Lemke1,2, Miriam Gömmel1,2, Martin Pauli9, Yunxiang Liao1,2, Peter Häring10, Stefan Pusch3,4, Verena Herl11, Christian Steinhäuser11, Damir Krunic12, Mostafa Jarahian13, Hrvoje Miletic14, Anna S Berghoff15, Oliver Griesbeck16, Georgios Kalamakis17, Olga Garaschuk17, Matthias Preusser18, Samuel Weiss19,20,21, Haikun Liu22, Sabine Heiland8, Michael Platten1,23, Peter E Huber24,25, Thomas Kuner5, Andreas von Deimling3,4, Wolfgang Wick1,2, Frank Winkler1,2.   

Abstract

Astrocytic brain tumours, including glioblastomas, are incurable neoplasms characterized by diffusely infiltrative growth. Here we show that many tumour cells in astrocytomas extend ultra-long membrane protrusions, and use these distinct tumour microtubes as routes for brain invasion, proliferation, and to interconnect over long distances. The resulting network allows multicellular communication through microtube-associated gap junctions. When damage to the network occurred, tumour microtubes were used for repair. Moreover, the microtube-connected astrocytoma cells, but not those remaining unconnected throughout tumour progression, were protected from cell death inflicted by radiotherapy. The neuronal growth-associated protein 43 was important for microtube formation and function, and drove microtube-dependent tumour cell invasion, proliferation, interconnection, and radioresistance. Oligodendroglial brain tumours were deficient in this mechanism. In summary, astrocytomas can develop functional multicellular network structures. Disconnection of astrocytoma cells by targeting their tumour microtubes emerges as a new principle to reduce the treatment resistance of this disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26536111     DOI: 10.1038/nature16071

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  315 in total

1.  Neuro-oncology: Astrocytoma cells interconnect to resist radiotherapy.

Authors:  Hemi Malkki
Journal:  Nat Rev Neurol       Date:  2015-11-20       Impact factor: 42.937

2.  Glioma: Tumour cell teamwork.

Authors:  Lydia Shipman
Journal:  Nat Rev Cancer       Date:  2015-12-04       Impact factor: 60.716

3.  CNS cancer: Astrocytoma cells interconnect to resist radiotherapy.

Authors:  Hemi Malkki
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

4.  Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages.

Authors:  Zhihong Chen; James L Ross; Dolores Hambardzumyan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

Review 5.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

6.  A 3D topographical model of parenchymal infiltration and perivascular invasion in glioblastoma.

Authors:  Kayla J Wolf; Stacey Lee; Sanjay Kumar
Journal:  APL Bioeng       Date:  2018-04-01

7.  [Discovery of a new division system in brain and the regionalized drainage route of brain interstitial fluid].

Authors:  H B Han
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-18

8.  An orthotopic glioblastoma animal model suitable for high-throughput screenings.

Authors:  Linda Pudelko; Steven Edwards; Mirela Balan; Daniel Nyqvist; Jonathan Al-Saadi; Johannes Dittmer; Ingrid Almlöf; Thomas Helleday; Lars Bräutigam
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

9.  The advanced development of Cx43 and GAP-43 mediated intercellular networking in IDH1 wildtype diffuse and anaplastic gliomas with lower mitotic rate.

Authors:  Aleksandrs Krigers; Patrizia Moser; Helga Fritsch; Matthias Demetz; Konstantin Brawanski; Claudius Thomé; Christian F Freyschlag
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-26       Impact factor: 4.553

10.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Authors:  Wolfgang Wick; Susan Dettmer; Anne Berberich; Tobias Kessler; Irini Karapanagiotou-Schenkel; Antje Wick; Frank Winkler; Elke Pfaff; Benedikt Brors; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; Andreas Eisenmenger; Andreas von Deimling; David T W Jones; Stefan M Pfister; Felix Sahm; Michael Platten
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.